BACKGROUND: The behavior of neuroendocrine neoplasms is poorly defined, and predictors of outcome after surgical resection have yet to be identified. Consequently, guidelines for treatment remain unclear. Current pathologic classification systems do not permit meaningful discrimination of hepatic neuroendocrine neoplasms. METHODS: The authors reviewed prospectively maintained databases from 2 institutions of patients who underwent hepatic resection for neuroendocrine neoplasms between 1990 and 2006. Patient, tumor, and operative characteristics were analyzed to identify factors associated with overall survival, progression-free survival, and symptom control. Hepatic neoplasms were stratified by using a 3-tier pathologic classification system based on the number of mitotic figures and the presence of tumor necrosis that was recently validated for pancreatic neuroendocrine neoplasms. RESULTS: Seventy patients were identified from the databases. Low-grade, intermediate-grade, and high-grade neoplasms were identified in 53%, 37%, and 10% of patients, respectively. After a median follow-up of 51 months, the median overall survival for all patients was 91 months, and it was 108 months when 7 patients with high-grade neuroendocrine carcinomas were excluded. Progressive disease was eventually observed in 81% of patients, and the median progression-free survival was 17 months. The median time to the onset of symptoms was 39 months for patients who presented with hormonal symptoms and 80 months for all patients. Histologic grade was associated with poorer overall and progression-free survival. CONCLUSIONS: When performed in a context of aggressive multimodality therapy, long-term outcomes after partial hepatectomy for hepatic neuroendocrine neoplasms were favorable; however, disease progression was eventually observed in the majority of patients. Several oncologic variables were associated with significant differences in survival after resection. A novel pathologic classification system appears to enhance prognostic stratification of patients with hepatic neuroendocrine neoplasms. (Copyright) 2008 American Cancer Society.
BACKGROUND: The behavior of neuroendocrine neoplasms is poorly defined, and predictors of outcome after surgical resection have yet to be identified. Consequently, guidelines for treatment remain unclear. Current pathologic classification systems do not permit meaningful discrimination of hepatic neuroendocrine neoplasms. METHODS: The authors reviewed prospectively maintained databases from 2 institutions of patients who underwent hepatic resection for neuroendocrine neoplasms between 1990 and 2006. Patient, tumor, and operative characteristics were analyzed to identify factors associated with overall survival, progression-free survival, and symptom control. Hepatic neoplasms were stratified by using a 3-tier pathologic classification system based on the number of mitotic figures and the presence of tumornecrosis that was recently validated for pancreatic neuroendocrine neoplasms. RESULTS: Seventy patients were identified from the databases. Low-grade, intermediate-grade, and high-grade neoplasms were identified in 53%, 37%, and 10% of patients, respectively. After a median follow-up of 51 months, the median overall survival for all patients was 91 months, and it was 108 months when 7 patients with high-grade neuroendocrine carcinomas were excluded. Progressive disease was eventually observed in 81% of patients, and the median progression-free survival was 17 months. The median time to the onset of symptoms was 39 months for patients who presented with hormonal symptoms and 80 months for all patients. Histologic grade was associated with poorer overall and progression-free survival. CONCLUSIONS: When performed in a context of aggressive multimodality therapy, long-term outcomes after partial hepatectomy for hepatic neuroendocrine neoplasms were favorable; however, disease progression was eventually observed in the majority of patients. Several oncologic variables were associated with significant differences in survival after resection. A novel pathologic classification system appears to enhance prognostic stratification of patients with hepatic neuroendocrine neoplasms. (Copyright) 2008 American Cancer Society.
Authors: Steven C Katz; Charan Donkor; Kristen Glasgow; Venu G Pillarisetty; Mithat Gönen; N Joseph Espat; David S Klimstra; Michael I D'Angelica; Peter J Allen; William Jarnagin; Ronald P Dematteo; Murray F Brennan; Laura H Tang Journal: HPB (Oxford) Date: 2010-12 Impact factor: 3.647
Authors: Linda S Sher; David M Levi; Julie S Wecsler; Mary Lo; Lydia M Petrovic; Susan Groshen; Lingyun Ji; Teresa Diago Uso; A Joseph Tector; Ann S Hamilton; J Wallis Marsh; Myron E Schwartz Journal: J Surg Oncol Date: 2015-07-14 Impact factor: 3.454
Authors: Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Yi Lv; Fabio Bagante; Luca Aldrighetti; George A Poultsides; Todd W Bauer; Ryan C Fields; Shishir Kumar Maithel; Hugo P Marques; Matthew Weiss; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2017-07-20 Impact factor: 3.452
Authors: Nikiforos Ballian; Agnes G Loeffler; Victoria Rajamanickam; Peter A Norstedt; Sharon M Weber; Clifford S Cho Journal: HPB (Oxford) Date: 2009-08 Impact factor: 3.647